Narumi Harada-Shoji1, Tomoyoshi Soga2, Hiroshi Tada3, Minoru Miyashita3, Mutsuo Harada4, Gou Watanabe3, Yohei Hamanaka3, Akiko Sato3, Takashi Suzuki5, Akihiko Suzuki6, Takanori Ishida3. 1. Department of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan. n.harada@med.tohoku.ac.jp. 2. Institute for Advanced Biosciences, Keio University, Yamagata, Japan. 3. Department of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan. 4. Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan. 5. Department of Pathology and Histotechnology, Tohoku University Graduate School of Medicine, Sendai, Japan. 6. Department of Breast and Endocrine Surgery, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Abstract
INTRODUCTION: Metabolomics has recently emerged as a tool for understanding comprehensive tumor-associated metabolic dysregulation. However, only limited application of this technology has been introduced into the clinical setting of breast cancer. OBJECTIVES: The aim of this study was to determine the feasibility of metabolome analysis using routine CNB/VAB samples from breast cancer patients and to elucidate metabolic signatures using metabolic profiling. METHODS: After breast cancer screenings, 20 consecutive patients underwent CNB/VAB, and diagnosed with benign, DCIS and IDC by histology. Metabolome analysis was performed using CE-MS. Differential metabolites were then analyzed and evaluated with MetaboAnalyst 4.0. RESULTS: We measured 116-targeted metabolites involved in energy metabolism. Principal component analysis and unsupervised hierarchical analysis revealed a distinct metabolic signature unique to namely "pure" IDC samples, whereas that of DCIS was similar to benign samples. Pathway analysis unveiled the most affected pathways of the "pure" IDC metabotype, including "pyrimidine," "alanine, aspartate, and glutamate" and "arginine and proline" pathways. CONCLUSIONS: Our proof-of-concept study demonstrated that CE-MS-based CNB/VAB metabolome analysis is feasible for implementation in routine clinical settings. The most affected pathways in this study may contribute to improved breast cancer stratification and precision medicine.
INTRODUCTION: Metabolomics has recently emerged as a tool for understanding comprehensive tumor-associated metabolic dysregulation. However, only limited application of this technology has been introduced into the clinical setting of breast cancer. OBJECTIVES: The aim of this study was to determine the feasibility of metabolome analysis using routine CNB/VAB samples from breast cancerpatients and to elucidate metabolic signatures using metabolic profiling. METHODS: After breast cancer screenings, 20 consecutive patients underwent CNB/VAB, and diagnosed with benign, DCIS and IDC by histology. Metabolome analysis was performed using CE-MS. Differential metabolites were then analyzed and evaluated with MetaboAnalyst 4.0. RESULTS: We measured 116-targeted metabolites involved in energy metabolism. Principal component analysis and unsupervised hierarchical analysis revealed a distinct metabolic signature unique to namely "pure" IDC samples, whereas that of DCIS was similar to benign samples. Pathway analysis unveiled the most affected pathways of the "pure" IDC metabotype, including "pyrimidine," "alanine, aspartate, and glutamate" and "arginine and proline" pathways. CONCLUSIONS: Our proof-of-concept study demonstrated that CE-MS-based CNB/VAB metabolome analysis is feasible for implementation in routine clinical settings. The most affected pathways in this study may contribute to improved breast cancer stratification and precision medicine.
Entities:
Keywords:
Breast cancer; CE–MS; Metabolome analysis; Needle breast biopsy
Authors: Anna K Casasent; Aislyn Schalck; Ruli Gao; Emi Sei; Annalyssa Long; William Pangburn; Tod Casasent; Funda Meric-Bernstam; Mary E Edgerton; Nicholas E Navin Journal: Cell Date: 2018-01-04 Impact factor: 41.582
Authors: Sue C Kaste; Scott E Snyder; Monika L Metzger; John T Sandlund; Scott C Howard; Matthew Krasin; Barry L Shulkin Journal: J Nucl Med Date: 2016-09-08 Impact factor: 10.057
Authors: Fabricio Loayza-Puch; Koos Rooijers; Levi C M Buil; Jelle Zijlstra; Joachim F Oude Vrielink; Rui Lopes; Alejandro Pineiro Ugalde; Pieter van Breugel; Ingrid Hofland; Jelle Wesseling; Olaf van Tellingen; Axel Bex; Reuven Agami Journal: Nature Date: 2016-02-15 Impact factor: 49.962
Authors: Lindsey A Torre; Farhad Islami; Rebecca L Siegel; Elizabeth M Ward; Ahmedin Jemal Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-02-21 Impact factor: 4.254